Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC

Clin Lung Cancer. 2024 Jan;25(1):e58-e61. doi: 10.1016/j.cllc.2023.08.012. Epub 2023 Aug 30.

Authors

Kevin Lu¹, Brian D Woodward¹, Joshua Boys², Mark Onaitis², Hatim Husain³

Affiliations

¹ Department of Medicine, University of California, San Diego, La Jolla, CA.
² Department of Surgery, University of California, San Diego, La Jolla, CA.
³ Department of Medicine, University of California, San Diego, La Jolla, CA. Electronic address: [email protected].

PMID: 37852849
DOI: 10.1016/j.cllc.2023.08.012

No abstract available

Keywords: Circulating tumor DNA; EGFR mutation; Neoadjuvant therapy; Non-small cell lung cancer; Osimertinib.

Publication types

Case Reports

MeSH terms

Acrylamides*
Aniline Compounds*
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
ErbB Receptors / genetics
Humans
Indoles*
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Mutation / genetics
Neoadjuvant Therapy
Protein Kinase Inhibitors / therapeutic use
Pyrimidines*

Substances

osimertinib
ErbB Receptors
Protein Kinase Inhibitors
EGFR protein, human
Acrylamides
Aniline Compounds
Indoles
Pyrimidines